Adoptive immunotherapy is a novel approach to treating patients with cancer, utilizing as therapy a patient's own peripheral blood lymphocytes that have been activated by incubation with interleukin-2 (IL-2). These cells develop the ability to mediate tumor regression in vivo and are referred to as
Apheresis techniques in lymphokine-activated killer cell production
โ Scribed by Irena Sniecinski; Kim Sentinella; Kim Margolin; Bonnie Mills
- Publisher
- John Wiley and Sons
- Year
- 1988
- Tongue
- English
- Weight
- 385 KB
- Volume
- 4
- Category
- Article
- ISSN
- 0733-2459
No coin nor oath required. For personal study only.
โฆ Synopsis
Adoptive transfer of autologous lymphokine-activated killer cells (LAK) in conjunction with recombinant interleukin-2 (rIL-2) has been reported to produce significant regression in metastatic disease in patients with advanced cancer. In an effort to confirm the results reported by the Surgery Branch of the National Cancer Institute, the same IL-2/LAK regimen was used in cancer patients at six extramural cancer centers. In this report we will review our experience with mononuclear cell removal from the blood of cancer patients using apheresis technology and extracorporeal handling of these cells to generate a selective, highly cytotoxic cell population.
๐ SIMILAR VOLUMES
In the past year, natural killer cells have been the subject of much active investigation. The analysis of the effect of cytokines on the generation, proliferation and function of natural killer cells, and the definition of the lymphokines that they produce, have been particularly important areas of
Objective. To determine the ability of T lymphocytes and natural killer (NK) cells from patients with systemic sclerosis (SSc) to respond to cytokines and to generate immune effector cells. Methods. The numbers and percentages of peripheral blood T and NK cells were examined by 2-color flow cytometr